A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Atezolizumab (Primary) ; Talimogene laherparepvec (Primary)
- Indications Breast cancer; Colorectal cancer
- Focus Adverse reactions
- Sponsors Amgen
- 05 Oct 2017 Planned End Date changed from 20 Dec 2020 to 25 Apr 2021.
- 05 Oct 2017 Planned primary completion date changed from 11 Feb 2019 to 24 Jun 2019.
- 05 Oct 2017 Planned initiation date changed from 29 Sep 2017 to 2 Feb 2018.